The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IP: Use at 1 - 4 µg/mg of lysate.
WB: 1/5,000 - 1/20,000. Detects a band of approximately 64 kDa (predicted molecular weight: 61 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both indepentently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of MLL1; it promotes leukemogenesis though association with MLL-rearranged oncoproteins, such as MLL-MLLT3/AF9 and MLL-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors.
Found in adrenal and parathyroid glands, kidney and heart.
Involvement in disease
Defects in CDC73 are a cause of familial isolated hyperparathyroidism (FIHP) [MIM:145000]; also known as hyperparathyroidism type 1 (HRPT1). FIHP is an autosomal dominant disorder characterized by hypercalcemia, elevated parathyroid hormone (PTH) levels, and uniglandular or multiglandular parathyroid tumors. Defects in CDC73 are the cause of hyperparathyroidism-jaw tumor syndrome (HPT-JT) [MIM:145001]; also known as hyperparathyroidism type 2 (HRPT2) or familial primary hyperparathyroidism with multiple ossifying jaw fibromas. HPT-JT is an autosomal dominant, multiple neoplasia syndrome primarily characterized by hyperparathyroidism due to parathyroid tumors. Thirty percent of individuals with HPT-JT may also develop ossifying fibromas, primarily of the mandible and maxilla, which are distinc from the brown tumors associated with severe hyperparathyroidism. Kidney lesions may also occur in HPT-JT as bilateral cysts, renal hamartomas or Wilms tumors. Defects in CDC73 are a cause of parathyroid carcinoma (PRTC) [MIM:608266]. These cancers characteristically result in more profound clinical manifestations of hyperparathyroidism than do parathyroid adenomas, the most frequent cause of primary hyperparathyroidism. Early en bloc resection of the primary tumor is the only curative treatment.
Cell division cycle 73 Paf1/RNA polymerase II complex component like protein antibody
Cell division cycle protein 73 homolog antibody
HPT JT antibody
HRPT 2 antibody
Hyperparathyroidism 2 (with jaw tumor) antibody
Hyperparathyroidism 2 antibody
Hyperparathyroidism 2 protein antibody
Paf1/RNA polymerase II complex component antibody
Western blot - HRPT2 antibody (ab70533)
All lanes : Anti-HRPT2 antibody (ab70533) at 0.1 µg/ml
Lane 1 : Whole cell lysate from 293T cells at 10 µg Lane 2 : Whole cell lysate from 293T cells at 20 µg Lane 3 : Whole cell lysate from 293T cells transfected
with a HRPT2 expression construct at 10 µg
Detection of Human HRPT2 (approximately 64 kDa) by Immunoprecipitation in whole cell lysate from 293T cells (10 mg for IP) in the presence or absence of blocking peptide, using ab70533 (BL648) at 3 µg/10mg lysate for IP and at 0.2 µg/ml for subsequent WB detection.